BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 27, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Oct. 4, 2019

View Archived Issues

Researchers test the first neuroprosthetic leg, now aim for a larger, longer study

Arm and hand prosthetics have long been the focus for researchers aiming to offer sensation as well as more precise and easily controlled movement by connecting patient nerves to sensors in the prosthetic. But now that effort has been extended to leg prosthetics as well. Read More

Trump promises quicker Medicare coverage for breakthrough technologies

Read More

Genomictree builds its U.S. branch for marketing colon cancer diagnostics kit

HONG KONG – South Korean biomarker-based molecular diagnostic firm Genomictree Inc. has built a U.S. unit in Pasadena, Calif., with an investment of KRW12 billion (US$10 million). The Daejeon, South Korean-based company first disclosed its plan to build the U.S. branch in March. Read More

Regulatory front

Read More

Financings

Read More

Daily M&A

Read More

Appointments and advancements

Read More

Other news to note

Read More

Product clinical data for Oct. 3, 2019

Read More

Product regulatory actions for Oct. 3, 2019

Read More

BioWorld MedTech's Diagnostics Extra

Read More

Angiodynamics to pay up to $66M for Eximo Medical and its laser atherectomy technology

Angiodynamics Inc., of Latham, N.Y., is picking up Rehovot, Israel-based Eximo Medical Ltd. for $46 million up front and up to $20 million of contingent consideration related to certain technical and revenue milestones. Eximo offers laser atherectomy technology that is in a limited launch. Read More

Exogenesis gets FDA OK to market first hernia mesh with nano-modified surface

The FDA has granted 510(k) clearance to the first hernia mesh featuring a nanometer-level surface texture, enabling better post-implant tissue ingrowth and reducing the incidence of adverse reactions. The Exogenesis Hernia Mesh, by Billerica, Mass.-based Exogenesis Corp., is indicated for the repair of abdominal wall hernias and deficiencies that require reinforcement to stabilize the condition and achieve a positive surgical outcome. The company expects to launch the product nationwide in 2020. Read More

Paper proposes a code of ethics for AI in radiology

The field of artificial intelligence (AI) in medical practice is in its infancy, but a group of medical societies has published a paper that proposes the development of a code of ethics for artificial intelligence (AI) in radiology. The paper underscores a number of concerns, including that some developers fail to fully appreciate the potential consequences of seemingly innocent slip-ups in the development and validation of that algorithm. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld
    Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
  • 3D rendering of skin cells and elastin with collagen layer

    First-in-class pan-inflammasome blocker for hidradenitis suppurativa

    BioWorld Science
    Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
  • Illustration of cancer cell in crosshairs being destroyed

    RX-10616 improves radiotherapy efficacy in HNSCC

    BioWorld Science
    Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing